Table 2 Ongoing clinical trials of daratumumab in multiple myeloma
From: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
NCT number | Title | Phase | Number | Recruitment |
|---|---|---|---|---|
NCT02116569 | A study of daratumumab in Japanese participants with relapsed or refractory multiple myeloma | 1 | 9 | Completed |
NCT02497378 | A study of JNJ-54767414 (daratumumab) in combination with bortezomib and dexamethasone (D-Vd) in Japanese participants with relapsed or refractory multiple myeloma | 1 | 6 | Recruiting |
NCT02519452 | A study of daratumumab with the addition of recombinant human hyaluronidase (rHuPH20) for the treatment of participants with relapsed or refractory multiple myeloma | 1 | 128 | Recruiting |
NCT02626481 | Study of daratumumab in combination with dexamethasone in resistant or refractory multiple myeloma | 2 | 64 | Recruiting |
NCT02316106 | A study to evaluate 3 dose schedules of daratumumab in participants with smoldering multiple myeloma | 2 | 120 | Recruiting |
NCT02419118 | Monoclonal antibodies for treatment of multiple myeloma. Emphasis on the CD38 antibody daratumumab | 2/3 | 50 | Recruiting |
NCT02076009 | A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma | 3 | 571 | Active, not recruiting |
NCT02136134 | Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma | 3 | 497 | Active, not recruiting |
NCT02541383 | A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia) | 3 | 1080 | Recruiting |
NCT02252172 | Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in participants with previously untreated multiple myeloma | 3 | 730 | Recruiting |
NCT02195479 | A study of combination of daratumumab and Velcade (bortezomib) melphalan-prednisone (DVMP) compared to Velcade melphalan-prednisone (VMP) in participants with previously untreated multiple myeloma | 3 | 700 | Recruiting |